APONTIS PHARMA AG · ISIN: DE000A3CMGM5 · Research | Analyses | Ratings

Buy

Original-Research: APONTIS PHARMA AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to APONTIS PHARMA AG Company Name: APONTIS PHARMA AG ISIN: DE000A3CMGM5 Reason for the research: Initiation of Coverage Recommendation: Buy from: 24.06.2024 Target price: EUR 17.00 Target price on sight of: 12 months Last rating change: - Analyst: Christian Orquera First Berlin Equity Research on 24/06/2024 initiated coverage on APONTIS PHARMA AG (ISIN: DE000A3CMGM5/...

+++ Corporate Insights +++- Company news, directors dealings, net short positions

Current analyst assessments

On this page you will find current analyst assessments of renowned research houses, which make their assessments on the business development of listed companies available for publication and distribution via our content partner EQS-Newswire.
Reset Filter
No analyst reports found. Please check the selected search criterion or try again later.
Info
The information presented here was provided by our content partner EQS. The assessments of the analyst houses were transmitted in the original via the news service EQS-Newswire for publication via the affiliated distribution networks.
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.